Lacto-N-decaose (LND) Production Service

CD BioGlyco is the world's leading technology company with rich experience. We devote to providing Technologies for HMO Production for clients all over the world. We will be your partner for life.

Oligosaccharides in Human Milk

There are a lot of structures in mammalian milk and colostrum, which are important for the nutrition and health of the suckling neonate. Over the past few decades, it is shown that some oligosaccharides, being characterized in human milk, have beneficial effects on health. For example, HMOs can promote the growth of bifidobacteria in neonates’ intestines, because they carry the so-called bifidogenic factor (Gal(1-3)GlcNAc). HMOs are selectively fermented by bifidobacteria and then they produce organic acids that cause pH to drop in the intestine. It is difficult for pathogens to grow in an environment with a low pH. And that motivates the production of mucin, improving the host’s resistance to infections.

Core Structure of Lacto-N-decaose (LND)

LDN is an oligosaccharide identified in breast milk. The Monosaccharide composition of LND is determined by methylation analysis to comprise one Glc (reducing end), five Gal (three non-reducing terminals), and four GlcNAc residues (Fig.1).

The core structure of LND. Fig.1 The core structure of LND. (CD BioGlyco)

LND Production Service

HMOs have been isolated from breast milk for research on structural identification and fundamental applications. But, this method is unsuitable for mass production. Because the reactions and steps are complex. Other approaches use the biosynthetic capacity of microbial cells. Mass oligosaccharides can be produced by coupling two or more distinct cell homogenates. Chemoenzymatic synthesis is another approach to produce HMOs. Glycosyltransferases are expressed recombinantly and used together with matching nucleotide-activated donor substrates and acceptors. It has been applied to build libraries of structurally diverse HMOs for research purposes. We produce LND in host cells, wherein the cell is genetically modified for the production of an oligosaccharide. The cell contains a nucleic acid sequence coding for a galactoside beta-1,3-N-acetylglucosaminyltransferase to synthesize glycosyltransferase thereby synthesizing LND. A membrane protein in the cell enables to transport of oligosaccharides and has a positive effect on the fermentative production of LND. Our method provides a good yield, specific productivity, and growth speed.

Advantages of Us

  • Good yield and mass production of HMOs
  • High-quality services
  • Comprehensive and reliable after-sales service

CD BioGlyco tops the global rankings in the field of biotechnology. We guarantee good after-sales service. Customers can contact our employees directly and we will reply quickly. If you are interested in our services, please feel free to contact us for more detailed information.

Reference

  1. Chai, W.; et al. Structural determination of novel lacto-N-decaose and its monofucosylated analogue from human milk by electrospray tandem mass spectrometry and 1H NMR spectroscopy. Arch Biochem Biophys. 2005, 434(1): 116-27.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.